Johnson & Johnson gets FDA approval for schizophrenia drug

12/8/2003 |

Drugmaker Johnson & Johnson announced it has received FDA approval for its schizophrenia drug, Risperdal, to treat bipolar I disorder, the most severe form of the disease. The company said users of the drug showed significant improvement over persons treated in a control group.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA